Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + ifosfamide + vincristine
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of doxorubicin (an anthracycline), ifosfamide (an alkylating agent), and vincristine (a vinca alkaloid). This combination is primarily used in the treatment of Ewing sarcoma and other sarcomas. The regimen works through multiple mechanisms to target cancer cells: doxorubicin intercalates with DNA and inhibits topoisomerase II, ifosfamide cross-links DNA strands, and vincristine binds to tubulin, disrupting microtubule formation and arresting cell division.
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on doxorubicin + ifosfamide + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + ifosfamide + vincristine.